Apr 20, 2021 7:30 am EDT Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
Apr 19, 2021 7:30 am EDT Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
Mar 25, 2021 7:30 am EDT Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
Mar 24, 2021 4:01 pm EDT Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
Mar 22, 2021 7:30 am EDT Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
Feb 22, 2021 7:30 am EST Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Feb 12, 2021 11:36 am EST New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
Feb 2, 2021 7:30 am EST Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
Jan 25, 2021 7:30 am EST Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Dec 21, 2020 12:20 pm EST Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
